Doconexent
Drug profile
Also known as: cervonic acid, docosahexaenoic acid, efalex
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Doconexent is a drug catalogued in DrugCentral. DrugCentral lists 7 molecular targets, including FFAR1, OXER1 and RXRA. Recorded indications include Breastfeeding (mother) and Pregnancy, function.
- Molecular targets: FFAR1, OXER1, RXRA and PTGS2 (7 listed in DrugCentral).
- Indications: Breastfeeding (mother) and Pregnancy, function.
- Molecular formula: C22H32O2; molecular weight 328.50 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Breastfeeding (mother)
- Pregnancy, function
Off-label uses (1)
- Prevention of Fetal Neural Tube Defects during Pregnancy
Mechanism & targets
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Free fatty acid receptor 1 | FFAR1 | agonist | EC50 6.00 |
| Oxoeicosanoid receptor 1 | OXER1 | unknown | IC50 5.70 |
| Retinoic acid receptor RXR-alpha | RXRA | unknown | Ki 5.20 |
| Prostaglandin G/H synthase 2 | PTGS2 | unknown | IC50 5.01 |
| Prostaglandin G/H synthase 1 | PTGS1 | unknown | IC50 4.82 |
| Aromatase | CYP19A1 | unknown | IC50 4.48 |
| Transient receptor potential cation channel subfamily A member 1 | Trpa1 | activator | EC50 4.40 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| — | FDA | — | — |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Child abuse | 175.2 |
| Epidural lipomatosis | 153.8 |
| Psoriatic arthropathy | 151.3 |
| Pneumonia aspiration | 133.0 |
| Juvenile idiopathic arthritis | 110.5 |
| Obesity | 99.9 |
| Coma | 97.5 |
| Type 2 diabetes mellitus | 95.6 |
| Mobility decreased | 94.4 |
| Pericarditis | 93.5 |
| Victim of child abuse | 89.6 |
| Rheumatic disorder | 88.8 |
Chemical structure
| Molecular formula | C22H32O2 |
|---|---|
| Molecular weight | 328.50 g/mol |
| CAS number | — |
| InChIKey | MBMBGCFOFBJSGT-KUBAVDMBSA-N |
| PubChem CID | 445580 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Doconexent used for?
DrugCentral lists the following indications for Doconexent: Breastfeeding (mother) and Pregnancy, function.
How does Doconexent work?
Its molecular targets in DrugCentral include FFAR1 (agonist), OXER1, RXRA and PTGS2.
What is the chemical formula of Doconexent?
Doconexent has the molecular formula C22H32O2 and a molecular weight of 328.50 g/mol.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4289 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL367149 — compound record and bioactivity
- PubChem CID 445580 — chemical identifiers
- DrugBank DB03756 — drug record
- FDA UNII ZAD9OKH9JC — substance identity
- DailyMed: FDA labels for Doconexent — current prescribing information (label search)
- UniProt O14842 (FFAR1) — target protein
- UniProt Q8TDS5 (OXER1) — target protein
- UniProt P19793 (RXRA) — target protein
- UniProt P11511 (CYP19A1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.